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Abstract
Background: Chronic multiple-site joint pain (MSJP) is common in older people and associated with poor outcomes,
yet under-researched. Our aim was to detail the clinical characteristics of people with MSJP and their utilisation of
therapies.
Methods: MSJP was defined as pain in at least one large joint and one other joint for >6 weeks in the last three
months. A mixed community, primary and secondary care cohort of people >50 years old underwent detailed
history and examination by a single clinician. Treatment utilisation was recorded comprehensively.
Results: 201 adults were recruited, 82 % women, mean age 63, BMI 31 kg/m2. Median number of painful joints
per patient was 6 (IQR 4–9; range 2–17); most common painful sites were knee (84 %), lower back (62 %) and
shoulder (47 %). 194/201 (96 %) had an osteoarthritis (OA) diagnosis, 155/194 (80 %) also had soft tissue pathology and
72 % had back problems. 85 % had OA at multiple sites. Upper and lower limb weakness was common (90 and 77 %
respectively). Lower limb weakness was significantly associated with obesity. Only 26 % had received written information
about their joints. Though 79 % had attended physiotherapy, the majority (93 %) had muscle weakness. Only 36 % of
overweight participants had accessed weight-loss support. Half of those with foot pain had seen a podiatrist or used
appliances. Multiple concurrent pharmacological therapies were used by 47 %.
Conclusion: MSJP represents a combination of OA, back pain and soft tissue disorders; muscle weakness is extremely
common. Therapies appear underutilised in people with MJSP. Identifying the reasons for this should guide effective
intervention research.
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Background
Musculoskeletal (MSK) problems are now the second
most significant cause of disability worldwide, with low
back pain remaining the leading specific cause of years
lived with disability, and osteoarthritis (OA) significantly
rising in importance [1]. Large epidemiological studies
have reported that chronic multiple-site joint pain
(MSJP) is more common than single joint problems in
older adults and is associated with poor outcomes [2, 3].
Increased numbers of painful joints is related to poor
physical function [3, 4] and increased work disability [5].
Despite the frequent prevalence of MSJP and the asso-
ciated poor outcomes, the characteristics of MSJP have
not been well described or researched. Of note, there
have been extremely few therapeutic trials in this area.
The majority of MSK pain trials have involved selecting
a single predominantly painful joint, whilst guidelines
have focused on individual disease areas such as OA or
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back pain [6, 7]. The effectiveness of currently available
therapies in people with MSJP is therefore not known. A
recent survey of the approach of UK general practitioners
(GPs) on pharmacological management of MSJP found
that most did aim to treat multiple-site pains concur-
rently, using the same therapies for all sites irrespective of
diagnosis [8].
Although clinicians have long recognised MSJP, the
lack of characterisation and understanding of this condi-
tion, and the lack of management strategies, in the con-
text of a rapidly ageing and increasingly obese society,
makes this an increasingly important area for further re-
search. The aim of this study was therefore to examine
the detailed clinical characteristics of people with MSJP
and their utilisation of therapeutic interventions.
Methods
Study population and eligibility criteria
Prospective participants were identified through the fol-
lowing sources: referral by general practitioners from pri-
mary care services; referral by physiotherapists from
musculoskeletal services; identification by clinicians within
secondary and tertiary care rheumatology, musculoskeletal
and orthopaedic clinics; patient public involvement orga-
nisations in West Yorkshire. Patients were screened via a
telephone interview and those meeting the inclusion cri-
teria were recruited.
The inclusion criteria were patients aged 50 years and
above, having pain in at least one large joint and one
other joint for more than six weeks within the last three
months, and capable of understanding and signing an in-
formed consent form. The definition of a large joint area
in this study included the spine, shoulders, elbows, hips,
knees and ankles. Exclusion criteria included i) previous
diagnosis of a primary inflammatory arthritis including
rheumatoid arthritis, gout, polymyalgia rheumatica or
connective tissue disease, ii) previous clinician-diagnosed
fibromyalgia, iii) a chronic medical condition requiring
long term use of oral corticosteroids or immunosup-
pressants and iv) unable or unwilling to give informed
consent.
Ethics, consent and permissions
Ethical approval was received from the Yorkshire and the
Humber (Leeds Central) Ethics Committee (Ref: 12/YH/
0345) and all participants gave written informed consent.
Design
The Leeds MSJP study involves observational, longitudinal
evaluation of this under-researched group; here we present
the baseline cross-sectional data. Participants completed a
series of questionnaires and underwent a detailed his-
tory and clinical examination of painful joints by a sin-
gle rheumatologist to document medical history and
musculoskeletal diagnoses. A patient and public involve-
ment group representative was involved in the develop-
ment of the study and design of the participant case
report form.
Information on age, gender, ethnicity, smoking status,
alcohol consumption, employment history and medical
co-morbidities, including joint related co-morbidities
(duration of joint pain, previous joint surgery and family
history), and comprehensive therapy use (current and
previous pharmacological therapies, including over-the-
counter (OTC), and local therapies) were recorded (see
Additional file 1). Clinical diagnoses for the painful joints
were based on established diagnostic criteria (Additional
file 1). Where diagnostic criteria were not available, the
clinician’s judgement was used. Where previous radio-
graphic information was available, this was used to sup-
port the clinical diagnosis. Upper limb strength was
measured using a Jamar hand dynamometer (Sammons
Preston Rolyan, Bolingbrook, IL, USA). Three attempts
were recorded (measured in pounds) for each hand,
and the three trials then averaged to create scores for
analysis. For lower limb muscle strength, the Medical
Research Council (MRC) scale was used. The MRC
scale is an established test for muscle grading on a 0 to
5 scale which has been previously shown to be reliable for
assessing lower limb weakness [9] (Additional file 1).
Participants completed a set of questionnaires that
asked about their joint pain and function over the past
week. Joint pain was also assessed using a manikin that
included the neck, upper back, lower back, shoulders, el-
bows, wrists, hands or fingers, thumbs, hips, groin, knees,
ankles, feet and ball of feet or toes. 11-point numerical rat-
ing scales were used to assess overall pain severity from all
joints and pain from the most painful joint.
Statistical analysis
Statistical analysis was carried out with Stata 13.1 software
(StataCorp LP, College Station, TX, USA) [10] and R
version 3.1.1 [11].
Descriptive statistics were used to describe the main
characteristics of the study population and are presented
as arithmetic mean (S.D) or medians where appropriate
for continuous variables and frequency and percentages
for categorical variables. The prevalence of pain at each
site was evaluated and correlations between reported pain
at each site compared with other sites using phi correlation
coefficients for binary data. These associations between
pain at pairs of sites were also explored using logistic
models and findings summarised using odds ratios (ORs)
and 95 % confidence intervals having adjusted for age and
sex. Muscle weakness was split into upper limb (based
on hand grip measurements) and lower limb (using
quadriceps strength measurements). For upper limb
strength, the average of 3 attempts from the dynamometer
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readings was used, these were then converted to kilograms
and the determination of whether an individual’s upper
limb was weak was adjusted based on their gender and
BMI. For males the cut offs were: (obese men < 40 kg;
overweight men <39 kg and normal men 37 kg) while in
female the cut off was uniformly 21 kg for one to be
considered to have weakness in that limb [12]. For
lower limb weakness any score less than 5 on the MRC
scale was considered as weakness for that limb. The
MRC scale grades weakness from 0 to 5 with zero being
no movement observed and five representing the muscle
fully contracting under resistance (Additional file 1). Asso-
ciations between site of muscle weakness (upper limb
weakness vs lower limb weakness) and associations be-
tween limb pain and muscle weakness (upper limb pain vs
upper limb weakness and lower limb weakness vs lower
limb pain), and also associations between muscle weak-
ness and specific joint pain (for example lower limb
weakness vs shoulder pain) were evaluated using chi-square
(Χ2) tests or Fisher’s exact test where appropriate. Differ-
ences were considered significant at P < 0.05.
Results
Among 424 people who were approached to participate
in the study, 210 people were screened. Three failed
screening (fibromyalgia n = 2, chronic illness on long
term corticosteroid therapy n = 1). Six participants with
pain limited to one large joint at the time of the baseline
assessment were not included in this analysis, leaving
201 participants. The mean ± SD age of the cohort was
63 ± 8.77 years (range 50–88) with 82 % of the cohort
being female. The mean BMI ± SD was 31 ± 6.42 kg/m2.
The mean duration of symptoms was 13.7 years (range
1–50). Table 1 shows the demographics and baseline
characteristics of the participants.
Examination findings
A total of 1342 painful joints were reported by partici-
pants with the median number of painful joints per person
being six (inter-quartile range 4–9, range 2–17). Periph-
eral joint pain was more common (82 %, 1107/1342) than
axial joint pain (18 %, 235/1342). The most commonly in-
volved painful joints by participant were the knee (84 %,
168/201), lower back (62 %, 125/201) and shoulder (47 %,
95/201), while the least commonly painful was the foot ex-
cluding the toes (12 %, 25/201). The joint with the highest
proportion of bilateral pain for that particular joint was
the hand/finger with 90 % of all the participants with in-
volvement in that joint having the condition affecting both
sides. This was followed by the thumb (71 %) and knee
(67 %).
Of the painful joints, 51 % (688/1342) were diagnosed
with OA, 30 % (408/1342) as having soft tissue path-
ology, 18 % with axial pain and 1 % non-specific joint
pain. Most participants (96 %, 194/201) had at least one
joint with an OA diagnosis, 81 % (162/201) had soft tis-
sue pathology and 77 % (155/194) had both OA and soft
tissue pathology. The prevalence of soft tissue pathology
was as common as OA in the upper limbs whereas OA
was more common in the lower limbs (Table 2).
The most common joint-specific diagnosis was knee
OA (20.8 %, 279/1342) followed by hand OA (11.2 %,
150/1342), trochanteric bursitis (9.6 %, 129/1342), suba-
cromial impingement syndrome (9.5 %, 128/1342), thumb
OA (9.2 %, 124/1342) and mechanical low back pain
(8.3 %, 112/1342). OA accounted for 99 % of knee pain,
92 % of hand pain, 86 % of foot/ball-of-foot/toe pain and
74 % of groin pain. 99 % of “hip” pain was due to trochan-
teric bursitis and 96 % of shoulder pain was due to suba-
cromial impingement syndrome.
Figure 1 shows the correlations of pain at each of the
25 anatomical sites. Pain was reported most frequently
in the right knee (73.6 %), left knee (66.2 %) and lower
back (62.1 %), and least often in the left ankle (8.0 %)
and right foot (8.5 %). Higher correlations were observed
for pain at bilateral joints (correlation for right hand and
left hand 0.91; left and right thumbs 0.75) and also ana-
tomically adjacent joints (shoulder with ipsilateral elbow
0.22 and groin and ipsilateral hip 0.21). Exploratory ana-
lyses using adjusted logistic regression models revealed
similar results but with wide confidence intervals. The
strongest associations were for pain at corresponding
sites bilaterally (ORs 706 for right and left hand, 95.2 for
right and left wrists, 56.2 for right and left thumb).
Higher ORs were also observed for pain at adjacent ana-
tomical sites in the upper limb (shoulder with ipsilateral
elbow, 4.7), and lower limb (right groin with ipsilateral
hip, 4.3) (Additional file 2: Table S1).
Muscle weakness
Four participants were unable to perform the handgrip
strength test due to hand pain, whilst 21 participants
were unable to complete the quadriceps strength test due
to lower limb pain. Muscle weakness was very common,
affecting the upper limb in 90 % (178/197), lower limb in
77 % (139/180), and both locations in 74 % (131/178).
There was a statistically significant association between
lower limb weakness and upper limb weakness (Χ2 =
20.21, p < 0.001). 90 % of participants with upper limb
pain had upper limb muscle weakness (149/165) and 78 %
with lower limb pain had lower limb weakness (134/172).
A statistically significant association was also demon-
strated between having lower limb weakness and having
shoulder pain (Χ2 = 8.39, p = 0.004), with 87 % of partici-
pants with shoulder pain having lower limb weakness com-
pared to 69 % of participants that had no reported shoulder
pain. In participants classified as obese (BMI > 30), 86 % of
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these reported lower limb weakness compared to 69 % of
those not classified as obese (Χ2 = 7.11, p = 0.008).
Therapy
Information
Provision of written information about the participant’s
joint problem was infrequent, with only 26 % (53/201)
recalling receiving such information or being referred to
other resources (e.g. internet website) following a GP or
specialist consultation.
Non-pharmacological treatment use
Non-pharmacological therapy use was infrequent. 173
participants were classed as being overweight, of which
36 % (62/173) recalled receiving weight loss treatment
(advice, written information, weight loss programme or
dietician input). The majority (79 %, 159/201) had
attended physiotherapy, 62 % (99/159) of these reported
continuing their exercises. Only half (51 %, 32/63) of
those with foot pain had used a podiatry service or a
shoe appliance. The most common reason for using spe-
cific non-pharmacological therapies were: physiotherapy
for knee OA (40 %, 81/201) and mechanical neck/back
pain (39 %, 79/201), exercise for knee OA (33 %, 67/
201), transcutaneous electrical nerve stimulation (TENS)
for back pain (16 %, 33/201), acupuncture for back pain
(21 %, 43/201), occupational therapy for hand/thumb
OA (10 %, 20/201), appliances for hand/thumb OA
(17 %, 34/201) and surgery for knee OA (20 %, 40/201).
Table 1 Demographics and baseline characteristics
Characteristic N (%)
Age, years, mean ± SD (range) 63 ± 8.77
(50–88)
Female 164 (82)






Current smoker 16 (8)
Previous smoker 81 (40)
Pack years, mean (range) 20 (1–75)
Alcohol consumption






Job activity (current or previous)
Heavy manual 94/192 (49)
Repetitive use of hands 21/192 (11)
Prolonged key boarding or typing 46/192 (24)
Prolonged standing 26/192 (14)
Median number of painful joints (IQR)
Overall in all participants 6 (4–9)
Current/previous smokers 7 (5–9)
Never smoked 6 (4–8)
Heavy manual job 7 (4–9)
Repetitive use of hands 7 (6–10)
Prolonged keyboarding/typing 6 (5–8)
Prolonged standing 6 (5–8)
Comorbidities
Cardiovascular disease (including hypertension,
ischaemic heart disease)
94 (47)
Pulmonary condition (including asthma, emphysema,
chronic bronchitis)
44 (22)





Table 1 Demographics and baseline characteristics (Continued)
Medical history
Joint replacement or fusion 57 (28)
Joint related soft tissue repair 53 (26)
Non-orthopaedic surgery 160 (80)
Family history of OA 135 (67)
BMI body mass index, IQR interquartile range
Table 2 Symptomatic joint and diagnosis
N (%) by region (%) of total number
of joints
Upper limb
Osteoarthritis 277/520 (53) 20
Soft tissue pathology 242/520 (47) 18
Lower limb
Osteoarthritis 411/588 (70) 31
Soft tissue pathology 166/588 (28) 12
Other (including referred pain) 11/588 (2) 1
Axial
Mechanical 219/235 (93) 16
Mechanical with radiculopathy 16/235 (7) 2
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Current pharmacological treatment use
Analgesia use was self-reported by 95 % of participants.
Of these, 71 % were using one or more prescription
medications, 74 % were using over-the-counter (OTC)
medication and 44 % were using both prescription and
OTC medications. Paracetamol (62 %) was the most
commonly used medication, with 62 % of paracetamol
users reporting this as OTC use. Opioids were the sec-
ond most common medication (51 %) and were mainly
reported as prescription medication (81 % for co-
codamol and 100 % other opioids) (Table 3). Oral co-
codamol (a fixed combination agent including paraceta-
mol and codeine) was the most commonly used opioid
medication, although other oral opioid (codeine phos-
phate, tramadol, oral morphine) use was also reported.
Transdermal opioid use was low (buprenorphine patch
and fentanyl patch). Most participants on opioid therapy
used a single opioid (77 %, 79/103) rather than combin-
ation oral opioid therapies (8 %, 8/103). NSAIDs were
used in 38 % (77/201), with the majority using a non-
selective NSAID (n = 71). Almost half of NSAID users
reported them as an OTC medication (44 %) Gastro-
protective agent (GPA) use among all non-selective
NSAID or COX-2 inhibitor users was 48 % (34/71) and
67 % (4/6) respectively. In participants taking OTC
NSAIDs, only 35 % of these used a GPA compared to
58 % of those taking prescription NSAIDs. Nutraceut-
ical use was limited with only 6 % reporting use of
glucosamine/chondroitin (Table 3).
Combination oral analgesia use was common (59 %,
113/191) and is outlined in Table 4. The most common
local pharmacological therapies were topical NSAID for
knee OA (43 %, 87/201) and intra-articular corticoster-
oid injection for subacromial impingement syndrome
(24 %, 49/201) and knee OA (24 %, 49/201).
Participants using non-selective NSAIDs or oral co-
codamol tended to use the analgesia for the most painful
joint rather than for overall pain. Most participants did
not use oral analgesia regularly, instead reporting to use
it only when in pain. In general efficacy was lowest among
participants that reported use of paracetamol (40 %,
50/124) and highest for NSAID (69 %, 49/71) and other
oral opioid users (62 %, 29/47). NSAID and co-codamol
users who found their medication to be effective were sig-
nificantly more likely to be using it for their most painful
joint (36/49, 73 % and 25/32, 78 % respectively) than for
all of their joints (13/49, 27 %, Χ2 = 5.22, p = 0.022; 7/32,
22 %, Χ2 = 7.82, p = 0.005). For paracetamol users and opi-
oid users effectiveness was equally as likely in participants
reporting use for their most painful joint or for overall
Fig. 1 Association between painful joints. Clockwise shading represents positive correlation and anti-clockwise shading represents negative correlation
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pain. Side effects were least common among paracetamol
users and most common in those using oral opioid ther-
apy. The overall pattern of current pharmacological ther-
apy use is described in Table 3. The most common reason
for stopping NSAID and all opioid (oral and transdermal)
medication was side effects whereas inefficacy was the
most common reason for stopping paracetamol and
glucosamine/chondroitin (Table 4).
Discussion
This is the first comprehensive study to examine the
detailed clinical characteristics of whole-body MSJP
and peoples’ utilisation of therapeutic interventions. This
study confirms that MSJP is a heterogeneous condition
comprised of a range of musculoskeletal pathologies. It
can be conceptualised as different combinations of periph-
eral joint OA, soft tissue disorders and mechanical back
pain.
In this study we included participants on the basis of
at least one large joint with pain. Previous studies have
specified knee OA as the index joint whilst others have
reported patients with multiple painful joints only if
they meet the ACR criteria for fibromyalgia; such studies
therefore do not necessarily reflect a true representation
of mechanical MSJP patients [13–15]. Many previous
MSJP studies, whether postal questionnaire or interview
based, have reported the number of painful joints without
characterisation of the involved joints [16]. Our study in-
cluded detailed clinical diagnosis of all involved joints,
both upper and lower limbs as well as the axial joints. We
found that nearly all participants had at least one joint
with an OA diagnosis, with most also having soft tissue
pathology in at least one joint. A previous study which
characterised upper limb joint pain reported that specific
soft-tissue disorders were common in the upper limb [17].
In line with this, we found that soft-tissue disorders were
common in the setting of MSJP especially in the upper
limb compared to the lower limbs. This study highlights
the heterogeneity of MSJP and demonstrates that a com-
bination of OA, back pain and soft tissue disorders is
common in this phenotypic setting.
Association between reported painful sites was stron-
gest for contralateral and adjacent sites, which may be
attributed to shared risk factors. Our findings are similar
to those from a 12,400 patient questionnaire study which
found similar associations (ORs) for self-reported pain at
10 anatomical sites [18].
Muscle weakness captured as a component of MSJP in
previous studies has been limited to the upper limbs.
Andersson et al. observed that individuals with general-
ised pain were more likely to have reduced hand muscle
strength compared to regional pain [19]. We recorded
Table 3 Overall pattern of current and previous medication use







Current drug use 124 (62) 71 (35) 6 (3) 58 (29) 47 (23) 14 (7) 12 (6) 4 (2)
Prescription drug 47 (38) 40 (56) 6 (100) 47 (81) 47 (100) 14 (100) 0 (0) 4 (100)
Reason for use
For most painful joint 68 (55) 46 (65) 3 (50) 36 (62) 22 (47) 2 (14) 1 (12) 2 (50)
For overall pain 56 (45) 25 (35) 3 (50) 22 (38) 25 (53) 12 (86) 11 (88) 2 (50)
Drug experience
Effective 50 (40) 49 (69) 3 (50) 32 (55) 29 (62) 6 (43) 7 (58) 3 (75)
Not effective 74 (60) 22 (31) 3 (50) 26 (45) 18 (38) 8 (57) 5 (42) 1 (25)
Side effects 3 (2) 12 (17) 6 (100) 24 (41) 24 (51) 3 (21) 0 (0) 0 (0)
Frequency of use
Regular use 28 (23) 18 (25) 5 (83) 19 (33) 22 (47) 12 (86) 11 (88) 4 (100)
Only when in pain 96 (77) 53 (75) 1 (17) 39 (67) 25 (53) 2 (14) 1 (12) 0 (0)
Previous drug use 52 (26) 119 (60) 4 (2) 87 (43) 53 (26) 9 (4) 70 (35) 5 (3)
Reason stoppedb
Side effects 1 (2) 78 (66) 4 (100) 52 (60) 43 (81) 4 (44) 4 (5) 4 (80)
Inefficacy 42 (81) 32 (26) 0 (0) 20 (23) 6 (11) 3 (33) 58 (83) 1 (20)
Loss of efficacy 9 (17) 7 (5) 0 (0) 7 (7) 1 (2) 0 (0) 3 (4) 0 (0)
Doesn’t like taking pills 0 (0) 1 (1) 0 (0) 5 (5) 1 (2) 2 (22) 4 (5) 0 (0)
Pain not severe enough 0 (0) 4 (3) 0 (0) 5 (5) 2 (0) 1 (11) 2 (3) 0 (0)
Values shown are number of participants (%)
aOther oral opioid includes codeine phosphate, tramadol and oral morphine
bSome participants had more than one reason for stopping medication
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both upper and lower limb muscle strength and found
that both were common in the setting of MSJP. Obesity
and shoulder pain showed a statistically significant as-
sociation with lower limb muscle weakness, whilst the
majority (87 %) of participants with shoulder pain had
lower limb weakness. These results suggest that obesity
and/or lower limb muscle weakness may contribute to
upper limb symptoms, perhaps through changes to the
use of the upper limbs, as has recently been reported [20].
The longitudinal data from this study may shed more light
on this putative biomechanical chain of events.
Previous studies have mainly recorded non-pharmacological
management in the setting of knee OA [21, 22]. The
majority (79 %) of participants in our study had attended a
physiotherapy appointment, with two-thirds of these re-
portedly continuing with exercises. This is considerably
higher than a recent OA study which reported physiother-
apy attendance of 46 % [23], but should be interpreted
with some caution since we did not capture exact num-
bers and details of sessions attended or details of adher-
ence. With regards to education, only a quarter of
participants recalled ever receiving written information
on their joint problem. Although this finding may be
influenced by recall bias, nonetheless it suggests that
there may be a lack of readily available information
(particularly about specific soft tissue disorders) at health
practices. This highlights an important area of manage-
ment that needs further consideration. The majority of
participants in this study were overweight/obese (86 %),
with only low numbers (36 %) reporting to have ever re-
ceived any type of weight management therapy. With
obesity rates increasing in Western societies, this remains
an important issue [24], particularly in light of a recent
randomised clinical trial which found that even a modest
weight reduction leads to improvement in function in
people with knee OA [25].
A recent GP survey revealed a belief that different
classes of analgesia have equal efficacy when used across
the range of different musculoskeletal pathologies that
comprise MSJP [8]. However, research is lacking to
examine efficacy across classes of oral analgesia for differ-
ent musculoskeletal pathologies, especially for opioids,
providing limited evidence-base for how to best approach
and treat MSJP. Compared to previous studies, this study
provides a more detailed description of analgesic use in
the setting of MSJP by separately reporting paracetamol,
co-codamol, non-selective NSAIDs, cox-2 inhibitors and
the different types of opioid (oral and transdermal), as well
as examining whether participants used agents for their
most painful joint or for overall pain. Although para-
cetamol was the most commonly used medication in
our study, opioid use was frequent with 48 % of partici-
pants using at least one opioid. Co-codamol was the
most commonly used opioid-containing analgesia, with
the large majority prescribed by the GP despite its
availability over the counter in the UK. The high use of
opioids in our cohort is in line with Grimby et al. who
suggested that in their older (>75 years) cohort, ‘light’
opioids were more likely to be used in MSJP than
NSAIDs [26]. In contrast our recent study of medication
use in people across Europe with OA, found that NSAIDs
were the most commonly used medication in this popula-
tion [27]. The higher use of opioids in the MSJP setting
may reflect increased incidence of co-morbidities in this
population, which preclude the use of NSAIDs or may
reflect physician preference of opioids. In this study,
80 % of participants reported at least one comorbidity
related to cardiac, pulmonary or gastrointestinal dis-
ease, demonstrating the high prevalence of comorbidi-
ties in this population.
Medication efficacy was reportedly higher among those
using NSAID or opioid therapy and lowest with paraceta-
mol use. Paracetamol was most commonly stopped due to
inefficacy. The lack of efficacy for paracetamol reported by
our population is in line with for the very low effect size
for paracetamol reported in recent systematic reviews of
OA therapies [28, 29]. Notably, for both NSAIDs and
Table 4 Analgesic combinations in 191 participants a






Combination therapy 113 (59)
Paracetamol
with NSAID 31 (16)
with opioids 30 (16)
with nutraceuticals 4 (2)
with NSAID and opioids 15 (8)
with NSAID and nutraceuticals 3 (2)
with opioids and nutraceuticals 3 (2)
NSAID
with opioids 12 (6)
with nutraceuticals 1 (1)
with opioids and nutraceuticals 1 (1)
Opioids
with nutraceuticals 2 (1)
Nutraceuticals
with NSAID and opioids 1 (1)
with all drugs 2 (1)
NSAID nonsteroidal anti-inflammatory drugs
a 10 participants did not take any medication
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co-codamol users, effectiveness was more likely to be
reported by participants using the therapy to reduce
pain in their most painful joint, compared to those
reporting to use the therapy to reduce their overall
pain. Most participants did not use oral analgesia on a
regular basis, perhaps offering opportunity for opti-
misation of therapy. Although there is no standard def-
inition for ‘under-utilisation’ in this context, the level of
utilisation of therapy which translates into efficacy in
such a population is unknown. Further work to estab-
lish appropriate levels of therapeutic utilisation and to
understand why therapies are currently under-utilised
in MSJP is required.
There are limitations to this study. Intra-rater reliabil-
ity for the different joint diagnoses, which were per-
formed by the single study clinician, was not examined;
however the clinician was a fully qualified Consultant
Rheumatologist. Although recruitment was from a var-
iety of sources including primary, secondary and tertiary
centres, most participants were from the hospital
rheumatology clinics. This may have introduced some
selection bias, as patients seen in these clinics may have
a more complex presentation compared to those man-
aged in primary care. When compared to another York-
shire community-based postal survey of 16,222 people
[2], the median number of painful joints in the present
cohort was higher (6 vs. 4). Inclusion of patients with at
least one large joint pain may also have introduced some
selection bias leading to a cohort mainly with large joint
OA, whilst the lack of radiological assessment may have
precluded accurate diagnosis of OA in joints not in-
cluded in ACR criteria e.g. shoulder, elbow and ankle.
Whilst we endeavored to capture as many therapies as
possible in this study the list was not exhaustive. As
such we did not collect information on non-
pharmacological therapies such as yoga and Tai Chi, and
their current uptake in this group is therefore unknown.
There are limitations in using the MRC scale to measure
lower limb weakness due to the subjective nature of the
test and lack of specificity, which may have resulted in
an under-estimation of the true prevalence of lower limb
weakness. As with other questionnaire-based studies,
findings may also be limited by recall bias.
Conclusions
In conclusion, MSJP reflects a combination of OA, soft
tissue disorders and mechanical back pain. Muscle weak-
ness and obesity are very common within this population.
Both systemic and local therapies appear to be underuti-
lised in people with MSJP. Identifying the reasons for this
should guide effective intervention research.
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